Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lucy Pan"'
Autor:
Dennis R. Benjamin, Eric J. Feldman, Che-Leung Law, Peter D. Senter, Sa A. Wang, Maitrayee Goswami, Timothy S. Lewis, Mechthild Jonas, Weiping Zeng, Ivan J. Stone, Martha E. Anderson, Michelle Ulrich, Kerry Klussman, Django Sussman, Ashley Cronkite, Lucy Pan, John Valliere-Douglass, Lori Westendorf, Roland B. Walter, Changpu Yu, May Kung Sutherland, Fu Li
Gating strategy, primary AML cytotoxicity assay,additional cell liens for pH2AX assay and caspase assay, and h7G3ec antibody sequence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d6621500ceec28e5ffa45ca4f5d714e
https://doi.org/10.1158/1535-7163.22505200
https://doi.org/10.1158/1535-7163.22505200
Autor:
Dennis R. Benjamin, Eric J. Feldman, Che-Leung Law, Peter D. Senter, Sa A. Wang, Maitrayee Goswami, Timothy S. Lewis, Mechthild Jonas, Weiping Zeng, Ivan J. Stone, Martha E. Anderson, Michelle Ulrich, Kerry Klussman, Django Sussman, Ashley Cronkite, Lucy Pan, John Valliere-Douglass, Lori Westendorf, Roland B. Walter, Changpu Yu, May Kung Sutherland, Fu Li
Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the majority of AML blasts, and there
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac8020bf88554cef4d7229c4d038ea4f
https://doi.org/10.1158/1535-7163.c.6537988.v1
https://doi.org/10.1158/1535-7163.c.6537988.v1
Autor:
Usha Sambamoorthi, Hannah Hazard, Michael Regier, Sita Kalidindi, Ami Vyas, Xiaoyun Lucy Pan, Suresh Madhavan
Publikováno v:
Journal of the National Comprehensive Cancer Network. 15:1401-1409
Background: Understanding the patterns of healthcare utilization and costs during the initial phase of care (12 months after breast cancer [BC] diagnosis) in older women (aged ≥65 years) is crucial in the allocation of Medicare resources. The objec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5320cdba8f46ede1dee3c70f030da44
https://doi.org/10.6004/jnccn.2017.0167
https://doi.org/10.6004/jnccn.2017.0167
Autor:
Sharon MacLachlan, Anjali Sharma, David Chandler, Xiaoyun Lucy Pan, Xiaoyan Shawn Li, Beth L Nordstrom, Hairong Xu, Junji Lin
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(1)
Objectives To provide an understanding of darbepoetin alfa dose patterns in cancer patients undergoing myelosuppressive chemotherapy starting from 2011. Study design This is a retrospective cohort study using a proprietary outpatient oncology databas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f1606ded8c867f6d3157d8ea27737e6
https://pubmed.ncbi.nlm.nih.gov/28814194
https://pubmed.ncbi.nlm.nih.gov/28814194
Publikováno v:
Tropical Cyclone Research and Review, Vol 11, Iss 4, Pp 265-276 (2022)
Southern Malawi is continuously affected by tropical cyclone-related floods (TCRFs), which have negative consequences on households' livelihoods, thereby displacing most households to neighbouring communities of Mozambique. The TCRFs have further thr
Externí odkaz:
https://doaj.org/article/2351b1ed06f84c9a95bc685d643749b5
Publikováno v:
Journal of Clinical Oncology. 36:13-13
13 Background: De-novo brain metastases (BM) occur in 15-35% of patients with ALK+ NSCLC, and the prevalence increases to as high as 60% over the course of first-line crizotinib therapy. Reports on the economic burden of brain metastases in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1f964fdd6858a55b8c704a91db52bb3
https://doi.org/10.1200/jco.2018.36.30_suppl.13
https://doi.org/10.1200/jco.2018.36.30_suppl.13
Autor:
Lucy Pan, John M. Brooks, Ming Lin, Michael Taylor, Brian K. Link, Julie M. Vose, Elizabeth A. Chrischilles, Kara B. Wright
Publikováno v:
Blood. 110:2612-2612
FL is incurable with standard therapy, with no consensus on best initial management strategy. Two critical choices - deferral of initial therapy and use or not of anthracyclines - are often “individualized” per clinical circumstances. To date, no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e75a6cdb2b7fd1f0d50ab6e2706f1b28
https://doi.org/10.1182/blood.v110.11.2612.2612
https://doi.org/10.1182/blood.v110.11.2612.2612